KR20200108125A - Anti-atopic dermatitis composition comprising mixture of plant extract as effective component - Google Patents
Anti-atopic dermatitis composition comprising mixture of plant extract as effective component Download PDFInfo
- Publication number
- KR20200108125A KR20200108125A KR1020190025600A KR20190025600A KR20200108125A KR 20200108125 A KR20200108125 A KR 20200108125A KR 1020190025600 A KR1020190025600 A KR 1020190025600A KR 20190025600 A KR20190025600 A KR 20190025600A KR 20200108125 A KR20200108125 A KR 20200108125A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- grape
- apple
- atopic dermatitis
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 53
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 53
- 239000000419 plant extract Substances 0.000 title abstract description 5
- 241000220225 Malus Species 0.000 claims abstract description 64
- 235000011430 Malus pumila Nutrition 0.000 claims abstract description 62
- 235000015103 Malus silvestris Nutrition 0.000 claims abstract description 62
- 235000012658 paprika extract Nutrition 0.000 claims abstract description 55
- 241000219095 Vitis Species 0.000 claims abstract description 54
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 54
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 54
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 54
- 239000001688 paprika extract Substances 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000036541 health Effects 0.000 claims abstract description 14
- 229940038487 grape extract Drugs 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 210000004027 cell Anatomy 0.000 abstract description 14
- 230000002757 inflammatory effect Effects 0.000 abstract description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 5
- 108090001007 Interleukin-8 Proteins 0.000 abstract description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 102100037850 Interferon gamma Human genes 0.000 abstract description 4
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 4
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 4
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 4
- 210000002510 keratinocyte Anatomy 0.000 abstract description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 17
- 201000004624 Dermatitis Diseases 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 240000004160 Capsicum annuum Species 0.000 description 12
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 12
- 239000001511 capsicum annuum Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- -1 grape extract Substances 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 235000021016 apples Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 식물 추출물의 혼합물, 보다 상세하게는 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 항아토피 피부염용 조성물에 관한 것이다. The present invention relates to a composition for anti-atopic dermatitis containing a mixture of plant extracts, and more particularly, a mixture of apple, grape and paprika extracts as an active ingredient.
아토피 피부염(atopic dermatitis)은 유전적, 환경적, 면역학적인 원인에 의해 발생하고, 피부 가장 바깥에서 보호벽 역할을 하는 각질층에 이상이 생긴 것으로 건조한 기후에서 더욱 심해지는 알레르기 질환이다. 아토피 피부염은 전 세계적으로 약 10~20%의 유병률을 보이며, 생후 1개월에서 1년 사이의 유아에게서 주로 발병하고 3세가 되면 어느 정도 완화되나 생활환경, 개인차 등에 의해 다시 재발할 수 있다. Atopic dermatitis (atopic dermatitis) is caused by genetic, environmental, and immunological causes, and is an allergic disease that is more severe in dry climates as an abnormality in the stratum corneum that acts as a protective wall at the outermost part of the skin. Atopic dermatitis has a prevalence rate of about 10-20% worldwide, and it mainly occurs in infants between 1 month and 1 year after birth, and it is relieved to some extent at the age of 3, but may recur again due to living environment and individual differences.
아토피 피부염의 주요 증상은 심한 가려움증, 피부건조, 발진, 진물, 부스럼딱지, 비늘 같은 껍질이 있는 피부(인비늘) 등으로 주로 만성 피부염증이 동반된다. 긁고 싶은 감정을 불러일으키는 가려움증은 히스타민(histamine)과 같은 가려움 매개 물질에 의해서 유도되는데, 정상인의 경우 긁으면 그 증상이 쉽게 완화되지만, 아토피 환자의 경우 긁으면 긁을수록 더욱 긁고 싶은 감정이 형성되어 더욱 더 심하게 긁게 된다. 아토피 환자의 긁는 행동으로 인해서 피부장벽이 붕괴되고 2차 감염을 유발하여 염증이 더욱 악화된다. 아토피 피부염은 일시적으로 완화될 수 있지만, 환경 및 식품 등의 자극원에 의해서 재발되어 악화될 수 있으며, 악화와 완화가 반복된다.The main symptoms of atopic dermatitis are severe itching, dry skin, rash, sores, scabs, scaly skin (phosphorus scales), etc., which is mainly accompanied by chronic skin inflammation. Itching, which arouses the feeling of wanting to scratch, is induced by an itching mediating substance such as histamine.In normal people, the symptoms are easily relieved when scratching, but in the case of atopic patients, the more scratched, the more the feeling of wanting to scratch is formed. Scratches. Due to the scratching behavior of atopic patients, the skin barrier collapses, causing secondary infection, and the inflammation worsens. Atopic dermatitis may be temporarily relieved, but may recur and worsen due to irritants such as the environment and food, and the worsening and alleviation are repeated.
이러한 아토피 피부염의 원인은 잘 알려져 있지 않으나 주로 유전적인 요소가 많고 면역 반응과 관련되어 있는 것으로 밝혀져 있으며, 그 외에 건조한 피부, 정상인에 비해 쉽게 피부 가려움증을 느끼는 특성, 세균, 바이러스 및 곰팡이 등에 의한 감염, 정서적 요인 및 환경적 요인 등이 서로 복합적으로 작용하여 일어나는 것으로 보인다. 아토피 피부염에 동반되는 염증은 과도한 면역세포 작용으로 인해 종양괴사인자-알파(TNF-α, tumor necrosis factor-α)와 인터루킨-1(IL-1, interleukin-l) 등의 염증성 사이토카인과 하이드록시 라디칼(·OH), 슈퍼옥사이드 라디칼(·O2-), 과산화수소(H2O2) 등과 같은 활성산소종(ROS, reactive oxygen species)을 대량생산하기 때문에 주변 조직의 손상을 야기한다.The cause of such atopic dermatitis is not well known, but it has been found to be mainly associated with many genetic factors and immune responses.In addition, dry skin, the property of feeling itchy skin more easily than normal people, infection by bacteria, viruses and fungi, It seems that emotional factors and environmental factors work in combination with each other. Inflammation associated with atopic dermatitis is caused by excessive immune cell action, causing inflammatory cytokines and hydroxy It causes damage to surrounding tissues because it mass-produces reactive oxygen species (ROS) such as radicals (·OH), superoxide radicals (·O 2 -), and hydrogen peroxide (H 2 O 2 ).
또한, 비만세포(mast cell)는 아토피 피부염을 비롯한 대부분의 알레르기성 질환에서 급성 및 만성 염증 질환을 일으키는 핵심 세포로 알려져 있다. 비만세포가 활성화되면, TNF-α, IL-1과 IL-6 등 염증성 사이토카인(inflammatory cytokines)의 생성뿐만 아니라 히스타민과 같은 가려움 유발물질(pruritogen)을 방출한다. 이와 같이 비만세포 유래 염증성 사이토카인은 염증반응을 더욱 촉진시키는 동시에 히스타민과 같은 가려움 유발물질의 분비를 더욱 촉진시켜 피부장벽을 붕괴시키는 원인이 된다. 따라서 부작용 없이 염증성 사이토카인과 가려움 매개물질을 억제시킬 수 있는 물질을 발굴한다면, 아토피 피부염을 비롯한 각종 알레르기성 질환을 제어하는데 효과적일 것이다.In addition, mast cells are known as core cells that cause acute and chronic inflammatory diseases in most allergic diseases including atopic dermatitis. When mast cells are activated, they not only produce inflammatory cytokines such as TNF-α, IL-1, and IL-6, but also release pruritogen such as histamine. In this way, mast cell-derived inflammatory cytokines further promote the inflammatory response and at the same time further promote the secretion of itching-inducing substances such as histamine, which causes the skin barrier to collapse. Therefore, if a substance that can suppress inflammatory cytokines and itching mediators without side effects is discovered, it will be effective in controlling various allergic diseases including atopic dermatitis.
아토피성 피부염에 대한 처방은 스테로이드제, 항히스타민제, 항생제 등과 같은 약물요법이 주로 이루어지고 있다. 스테로이드제(부신피질호르몬제)는 크게 소염작용과 면역억제 작용이 있고 효과가 우수하지만, 장기간 바르면 피부약화, 전신 호르몬증상, 중독성 등의 부작용이 나타날 수 있다. 최근 연구중인 아토피성 피부염의 치료 방향은 면역억제제를 사용하는 것과 새로운 항히스타민제를 사용하는 것이다. 그러나 항히스타민제만으로는 알레르기 반응을 완벽하게 차단하지는 못한다. 이는 알레르기 반응을 야기하는 화학전달물질이 히스타민만은 아니기 때문이다. 따라서 아토피성 피부염에 효과가 있으면서도 부작용이 없는 천연물을 이용한 새로운 아토피성 피부염 치료를 위한 조성물 개발이 요구되고 있다.Drug therapy such as steroids, antihistamines, and antibiotics is mainly used for prescription for atopic dermatitis. Steroids (corticosteroids) are largely anti-inflammatory and immunosuppressive, and have excellent effects, but if applied for a long time, side effects such as skin weakness, systemic hormonal symptoms, and addiction can occur. The treatment direction of atopic dermatitis under recent research is the use of immunosuppressants and the use of novel antihistamines. However, antihistamines alone do not completely block allergic reactions. This is because histamine is not the only chemical transporter that causes an allergic reaction. Therefore, there is a need to develop a composition for the treatment of atopic dermatitis using natural products that are effective against atopic dermatitis and do not have side effects.
한편, 화려하고 짙은 색깔을 가진 채소와 과일에는 비타민, 무기질, 섬유소가 풍부하게 들어 있으며, 특히 항산화 기능이 있는 피토케미컬(phytochemical) 성분이 많이 있어 건강 증진에 중요한 역할을 한다고 알려져 있다. 이러한 피토케미컬은 빨강, 주황, 노랑, 초록, 보라, 검정색의 채소와 과일에 특히 많이 함유 되어 있는 것으로 알려져 있으며, 색색의 채소와 과일은 색깔별로 각기 다른 효능을 지니고 있어 여려가지 채소와 과일을 꾸준히 섭취하면 과체중, 비만, 당뇨병 등의 만성질환 뿐만 아니라 변비, 대장암, 심장병, 고혈압, 암, 백내장, 폐질환 등을 예방할 수 있다고 알려져 있다. On the other hand, colorful and dark-colored vegetables and fruits are rich in vitamins, minerals, and fiber, and are known to play an important role in promoting health as there are many phytochemical components with antioxidant functions. These phytochemicals are known to be particularly high in vegetables and fruits of red, orange, yellow, green, purple, and black, and colored vegetables and fruits have different effects for each color, so they constantly consume a variety of vegetables and fruits. It is known that it can prevent not only chronic diseases such as overweight, obesity, and diabetes, but also constipation, colon cancer, heart disease, high blood pressure, cancer, cataracts, and lung diseases.
따라서 본 발명자들은 21세기 웰빙시대의 트랜드에 맞춰 컬러 푸드, 특히 남원지역에서 생산된 사과, 포도 및 파프리카에서 유효성분을 함유하는 추출물을 제조하고, 이들 추출물의 기능성을 평가하고자 하였다. Therefore, the present inventors prepared extracts containing active ingredients from color foods, especially apples, grapes and paprika produced in Namwon region, in accordance with the trend of the 21st century well-being, and tried to evaluate the functionality of these extracts.
한편, 한국등록특허 제1923343호에는 사과를 이용한 식초를 포함하는 아토피 피부염 개선용 조성물이 개시되어 있고, 한국등록특허 제0834850호에는 항알레르기성 비염, 항아토피성 피부염 또는 항만성천식 효과를 지니는 쑥, 구아바잎, 상엽 및 포도씨의 복합 생약 추출물을 유효성분으로 함유하는 기능성 조성물이 개시되어 있지만, 본 발명의 식물 추출물의 혼합물, 보다 상세하게는 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 항아토피 피부염용 조성물에 관해 개시된 바 없다.On the other hand, Korean Patent No. 1923343 discloses a composition for improving atopic dermatitis including vinegar using apples, and Korean Patent No. 0834850 discloses an antiallergic rhinitis, anti-atopic dermatitis, or mugwort having an anti-chronic asthma effect. , A functional composition containing a complex herbal extract of guava leaves, upper leaves and grape seeds as an active ingredient is disclosed, but a mixture of the plant extracts of the present invention, more specifically, a mixture of apple, grape and paprika extracts as an active ingredient There is no disclosed composition for anti-atopic dermatitis.
본 발명은 상기와 같은 요구에 의해 도출된 것으로, 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 항아토피 피부염용 조성물을 제공하고, 상기 사과, 포도 및 파프리카 추출물의 혼합물이 항아토피 피부염 효과가 있다는 것을 확인함으로써, 본 발명을 완성하였다. The present invention is derived from the above requirements, and provides a composition for anti-atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient, and the mixture of apple, grape and paprika extract has anti-atopic dermatitis effect. By confirming that there is, the present invention was completed.
상기 과제를 해결하기 위하여, 본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In order to solve the above problems, the present invention provides a health functional food composition for preventing or improving atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient.
또한, 본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient.
또한, 본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for preventing or improving atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient.
또한, 본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 개선용 의약외품을 제공한다. In addition, the present invention provides a quasi-drug for preventing or improving atopic dermatitis containing a mixture of apple, grape and paprika extracts as an active ingredient.
본 발명은 식물 추출물의 혼합물, 보다 상세하게는 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 항아토피 피부염용 조성물에 관한 것으로, 사과 추출물, 포도 추출물 또는 파프리카 추출물은 인간피부각질세포(HaCaT cell)에 TNF-α와 IFN-γ를 처리하여 증가된 염증 인자인 IL-6 및 IL-8의 분비를 억제하고, 사과, 포도 및 파프리카 추출물의 혼합물은 사과 추출물, 포도 추출물 또는 파프리카 추출물 단독에 비해 아토피 피부염이 유발된 동물모델에서 아토피 피부염을 개선하는 효과가 우수하였다. The present invention relates to a composition for anti-atopic dermatitis containing a mixture of plant extracts, more specifically, a mixture of apple, grape, and paprika extract as an active ingredient, wherein the apple extract, grape extract, or paprika extract comprises human skin keratinocytes (HaCaT cells) by treatment with TNF-α and IFN-γ to inhibit the secretion of IL-6 and IL-8, which are increased inflammatory factors, and a mixture of apple, grape and paprika extracts is applied to apple extract, grape extract, or paprika extract alone. In comparison, the effect of improving atopic dermatitis was excellent in the animal model caused by atopic dermatitis.
도 1은 본 발명에 따른 사과 추출물(A), 포도 추출물(B) 또는 파프리카 추출물(C) 처리에 따른 HaCaT 세포의 세포생존율을 확인한 결과이다.
도 2는 본 발명에 따른 사과 추출물(A), 포도 추출물(B) 또는 파프리카 추출물(C)이 HaCaT 세포에 TNF-α및 IFN-γ를 처리(T+I)하여 증가된 염증 인자인 IL-6 및 IL-8의 분비를 감소시키는 것을 확인한 결과이다.
도 3은 본 발명에 따른 사과 추출물, 포도 추출물, 파프리카 추출물 또는 이들의 혼합물이 아토피 피부염이 유발된 동물모델에서 아토피 피부염을 개선하는 효과를 나타낸 사진이다. DNFB는 피부염 유발 물질로, Blank를 제외한 모든 실험군의 제모된 등에 100㎕의 DNFB(2,4-dinitrofluorobenzene)를 일주일에 2회, 5주간 점적하여 피부염을 유발하였다. Blank는 피부염을 유발하지 않은 음성대조군이고, 덱사메타손(Dexamethason)은 양성대조군이다. 1 is a result of confirming the cell viability of HaCaT cells according to treatment with apple extract (A), grape extract (B) or paprika extract (C) according to the present invention.
Figure 2 is an apple extract (A), grape extract (B) or paprika extract (C) according to the present invention is treated with TNF-α and IFN-γ in HaCaT cells (T+I), an increased inflammatory factor IL- 6 and IL-8 secretion was confirmed to decrease.
3 is a photograph showing the effect of improving atopic dermatitis in an animal model in which an apple extract, grape extract, paprika extract or a mixture thereof according to the present invention is induced. DNFB is a dermatitis-inducing substance, and 100 µl of DNFB (2,4-dinitrofluorobenzene) was instilled twice a week for 5 weeks to induce dermatitis on the depilated backs of all experimental groups except for blanks. Blank is a negative control that did not cause dermatitis, and Dexamethasone is a positive control.
본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 개선용 건강기능식품 조성물에 관한 것이다. The present invention relates to a health functional food composition for preventing or improving atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient.
상기 사과, 포도 및 파프리카 추출물의 추출 용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물일 수 있으며, 바람직하게는 추출 용매로 에탄올을 이용하는 것이지만, 이에 한정하지 않는다. The extraction solvent of the apple, grape, and paprika extract may be water, a lower alcohol of C 1 ~ C 4 or a mixture thereof, and preferably, ethanol is used as the extraction solvent, but is not limited thereto.
상기 사과, 포도 및 파프리카 추출물의 혼합물의 혼합비는 사과 추출물: 포도 추출물: 파프리카 추출물이 0.5~1.5:0.5~1.5:0.1~1.2 중량비일 수 있고, 바람직하게는 사과 추출물: 포도 추출물: 파프리카 추출물이 1:1:0.5~1 중량비일 수 있으며, 더 바람직하게는 사과 추출물: 포도 추출물: 파프리카 추출물이 1:1:1 중량비 또는 2:2:1 중량비인 것이지만, 이에 제한되는 것은 아니다. The mixing ratio of the mixture of the apple, grape and paprika extract may be an apple extract: grape extract: paprika extract 0.5 to 1.5: 0.5 to 1.5: 0.1 to 1.2 weight ratio, preferably apple extract: grape extract:
상기 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조되는 것이 바람직하지만 이에 한정하는 것은 아니다. 본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 사과, 포도 및 파프리카 추출물의 혼합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. 상기 식품의 종류에는 특별한 제한은 없다. 상기 추출물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합체 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다. The health functional food composition is preferably prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto. When using the health functional food composition of the present invention as a food additive, the mixture of the apple, grape and paprika extract may be added as it is or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). In general, in the preparation of food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range. There is no particular limitation on the type of food. Examples of foods to which the extract can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages and vitamin complexes, and all health functional foods in the usual sense are included.
본 발명의 조성물을 건강 음료로 사용할 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 텍스트린, 사이클로텐스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100g당 일반적으로 약 0.01~0.04g, 바람직하게는 약 0.02~0.03g이다. 상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 중점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물은 100중량부 당 0.01~0.1중량부의 범위에서 선택되는 것이 일반적이다.When the composition of the present invention is used as a health drink, it may contain various flavoring agents or natural carbohydrates as an additional component, like a conventional drink. The natural carbohydrates described above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as texttrin and cyclotenstrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 g of the composition of the present invention. In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal focus agents, pH adjusters, stabilizers, preservatives, glycerin, alcohols , Carbonated beverages used in carbonated beverages, and the like. In addition, the composition of the present invention may contain flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These ingredients may be used independently or in combination. The proportion of these additives is not very important, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.
또한, 본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학 조성물에 관한 것이다. In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient.
본 발명의 조성물은 상기 유효성분 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더 포함할 수 있으며, 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형 제제에는 캡슐제, 산제, 과립제, 정제, 환제 등이 포함되며, 이러한 고형 제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁액, 에멀전, 시럽, 에어로졸 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성 용제 및 현탁 용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤 젤라틴 등이 사용될 수 있다. 비경구 투여 시 피부 외용 또는 복강 내, 직장, 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사 방식을 선택하는 것이 바람직하며, 가장 바람직하게는 피부 외용으로 사용한다. 피부 외용으로 사용하는 경우, 피부에 도포하는 연고제, 첩부제 또는 분무제의 제형으로 제조하는 것이 바람직하지만 이에 한정하지 않는다.The composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent in addition to the active ingredient, and may be in various oral or parenteral formulations. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include capsules, powders, granules, tablets, pills, and the like, and these solid preparations include at least one excipient in one or more compounds, such as starch, calcium carbonate, sucrose, or lactose ( lactose), gelatin, etc. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, emulsions, syrups, aerosols, and the like.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, fragrances, preservatives, etc. may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerol gelatin, and the like may be used. For parenteral administration, it is preferable to select an injection method for external use of the skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dura mater or cerebrovascular, most preferably for external use of the skin. In the case of external use of the skin, it is preferable to prepare it in a formulation of an ointment, patch, or spray applied to the skin, but is not limited thereto.
본 발명에 따른 약학 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에 있어서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효량의 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the level of the effective amount is the type, severity, and activity of the drug of the patient. , Sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.
본 발명의 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도에 따라 그 범위가 다양하며, 일일 투여량은 사과, 포도 및 파프리카 추출물의 혼합물의 양을 기준으로 0.01~2,000mg/kg이고, 바람직하게는 30~500mg/kg이고, 더욱 바람직하게는 50~300mg/kg이며, 하루 1~6회 투여될 수 있다. 본 발명의 조성물은 단독으로 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of disease, and the daily dosage is apple, grape and paprika extract. Based on the amount of the mixture of 0.01 ~ 2,000mg / kg, preferably 30 ~ 500mg / kg, more preferably 50 ~ 300mg / kg, it may be administered 1 to 6 times a day. The composition of the present invention can be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, and methods using biological response modifiers.
또한, 본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 개선용 화장료 조성물에 관한 것이다. In addition, the present invention relates to a cosmetic composition for preventing or improving atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient.
상기 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액, 파운데이션, 왁스 파운데이션 및 스프레이 중에서 선택된 어느 하나의 제형으로 제조되는 것이 바람직하지만 이에 한정하는 것은 아니다.The composition is prepared in any one formulation selected from solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion, foundation, wax foundation, and spray. It is preferable to be, but is not limited thereto.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1, 3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, a solvating agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene Glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. 본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판-부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as carrier components Etc. may be used. When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additionally chlorofluorohydro Propellants such as carbon, propane-butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 아세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a surfactant containing cleansing, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acetionate, imidazolinium derivative, methyltaurate, sarcosinate , Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty diethanolamide, vegetable oil, linoline derivative or ethoxylated glycerol fatty acid ester, and the like may be used.
본 발명의 화장료 조성물은 유효성분 이외에 추가로 동일 또는 유사한 기능을 나타내는 아토피 피부염을 개선할 수 있는 성분을 1종 이상 함유할 수 있다. The cosmetic composition of the present invention may contain one or more ingredients capable of improving atopic dermatitis exhibiting the same or similar function in addition to the active ingredient.
또한, 본 발명은 사과, 포도 및 파프리카 추출물의 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 개선용 의약외품에 관한 것이다. In addition, the present invention relates to a quasi-drug for preventing or improving atopic dermatitis containing a mixture of apple, grape and paprika extract as an active ingredient.
본 발명에서 용어, '의약외품'은 사람이나 동물의 질병을 치료, 경감, 처치 또는 예방할 목적을 사용되는 섬유, 고무제품 또는 이와 유사한 것, 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니하며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염형 예방을 위하여 살균, 살충 및 이와 유사한 용도로 사용되는 제제 중 하나에 해당하는 물품으로서, 사람이나 동물의 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것 및 사람이나 동물의 구조와 기능에 약리학적 영향을 줄 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것을 제외한 물품을 의미한다. 또한, 상기 의약외품은 피부외용제를 포함한다.In the present invention, the term'quasi-drug' refers to fibers, rubber products, or the like, which are used for the purpose of treating, alleviating, treating, or preventing diseases of humans or animals, and the action on the human body is weak or does not directly act on the human body, and Or non-machine and similar, as an article corresponding to one of the preparations used for sterilization, insecticide and similar purposes for the prevention of infectious types, for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals. It refers to items that are not instruments, machines, or devices among the items used, and items other than those that are not instruments, machines, or devices among items used for the purpose of having a pharmacological effect on the structure and function of humans or animals. In addition, the quasi-drug contains an external preparation for skin.
본 발명의 사과, 포도 및 파프리카 추출물의 혼합물을 의약외품 첨가물로 사용할 경우, 상기 사과, 포도 및 파프리카 추출물의 혼합물을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다. 상기 피부 외용제는 특별히 이에 제한되지 않는다.
When the mixture of apple, grape and paprika extract of the present invention is used as a quasi-drug additive, the mixture of apple, grape and paprika extract can be added as it is or can be used with other quasi-drug or quasi-drug ingredients, and can be used appropriately according to a conventional method. I can. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use. The external preparation for skin is not particularly limited thereto.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다.
Hereinafter, the present invention will be described in more detail using examples. These examples are only for describing the present invention in more detail, and it is apparent to those of ordinary skill in the art that the scope of the present invention is not limited thereto.
재료 및 방법Materials and methods
1. 사과, 포도 및 적색 파프리카 추출물의 제조1. Preparation of apple, grape and red paprika extract
사과, 포도, 적색 파프리카의 가식 부위를 60℃에서 24~48시간 동안 건조한 뒤 파우더 형태로 마쇄한 다음, 사과, 포도, 적색 파프리카 마쇄물 1 중량부에 대하여 10 부피부의 70%(v/v) 에탄올을 첨가하여 실온에서 12시간 동안 추출하였다.After drying the edible parts of apples, grapes, and red paprika at 60°C for 24 to 48 hours, pulverize them in powder form, and then 70% of 10 parts by volume (v/v) based on 1 part by weight of the ground apple, grape, and red paprika. ) Ethanol was added and extracted at room temperature for 12 hours.
상기 사과, 포도, 적색 파프리카 추출물은 종이 여과지로 여과한 후, 50℃에서 감압 농축하여 용매를 날려버린 다음 동결건조하여 세포실험 및 동물실험에 사용하였다.The apple, grape, and red paprika extracts were filtered through paper filter paper, concentrated under reduced pressure at 50° C. to blow off the solvent, and then lyophilized to be used in cell and animal experiments.
사과, 포도 및 적색 파프리카 추출물의 혼합물은 상기 사과, 포도, 적색 파프리카 추출물을 1:1:1 중량비 또는 2:2:1 중량비로 혼합하여 사용하였다.
A mixture of apple, grape and red paprika extract was used by mixing the apple, grape, and red paprika extract in a 1:1:1 weight ratio or 2:2:1 weight ratio.
2. 사과, 포도 및 적색 파프리카 추출물의 독성 평가-2. Evaluation of toxicity of apple, grape and red paprika extracts- MTTMTT 분석법 이용 Method use
사과, 포도, 적색 파프리카 추출물의 유효농도 및 독성농도를 설정하기 위하여 인간피부각질세포(HaCaT cell)에 추출물을 처리하여 실험하였다. HaCaT 세포를 3×105 농도로 24 웰 플레이트에 분주하고. 8시간 동안 안정화시킨 후, 각각의 추출물 시료를 다양한 농도(0.1, 1, 10, 100 및 1000㎍/mL)로 처리하였다. 24시간 동안 반응 후, 세포 독성 평가를 위하여 5mg/mL의 MTT 시약을 각 웰에 처리한 다음, 4시간 동안 반응시킨 후, MTT 시약과 세포내 미토콘드리아와 반응하여 생성된 포르마잔 결정(formazan crystal)을 DMSO에 녹여 흡광도를 흡광도 측정기를 통하여 540nm 파장 아래 측정하였다.
In order to establish the effective and toxic concentrations of apple, grape, and red paprika extracts, human skin keratinocytes (HaCaT cells) were treated with extracts and tested. HaCaT cells were dispensed into a 24-well plate at a concentration of 3×10 5 . After stabilizing for 8 hours, each extract sample was treated at various concentrations (0.1, 1, 10, 100 and 1000 μg/mL). After reaction for 24 hours, for the evaluation of cytotoxicity, 5 mg/mL of MTT reagent was treated in each well, and then reacted for 4 hours, and then formazan crystal produced by reacting with MTT reagent and intracellular mitochondria Was dissolved in DMSO and the absorbance was measured under a wavelength of 540 nm through an absorbance meter.
3. 사과, 포도 및 적색 파프리카 추출물의 항염증 효능 평가-ELISA 분석법 이용3. Evaluation of anti-inflammatory efficacy of apple, grape and red paprika extracts-using ELISA assay
항염증 활성 평가를 위하여 ELISA 분석법을 활용하여 염증 인자 발현을 확인하였다. HaCaT 세포주를 3×105의 농도로 24 웰 플레이트에 분주한 다음, 세포 안정화 단계를 거친 후, 다양한 농도(0.1, 1 및 10㎍/mL)의 추출물을 처리하고 4시간 동안 반응시켰다. 이후, TNF-α 및 IFN-γ를 Blank 군을 제외한 나머지 군에 10ng/mL 농도로 처리하였고, 37℃ 배양기에서 18시간 동안 배양하였다. 배양 후 각 웰의 배양액을 획득하여 12,000rpm에서 5분 동안 원심분리한 후, 상층액을 획득하였다. In order to evaluate the anti-inflammatory activity, the expression of inflammatory factors was confirmed using ELISA assay. The HaCaT cell line was dispensed into a 24-well plate at a concentration of 3×10 5 , and then subjected to a cell stabilization step, followed by treatment with extracts of various concentrations (0.1, 1 and 10 μg/mL) and reacted for 4 hours. Thereafter, TNF-α and IFN-γ were treated at a concentration of 10ng/mL in the remaining groups except for the Blank group, and cultured for 18 hours in a 37°C incubator. After incubation, the culture medium of each well was obtained, centrifuged at 12,000 rpm for 5 minutes, and then a supernatant was obtained.
ELISA 분석을 위해, 코팅 버퍼(Coating buffer)를 이용하여 IL(Interlukin)-6 및 IL-8의 1차 항체를 250:1의 부피비로 희석한 다음 96 웰 플레이트의 각 웰에 100㎕씩 분주한 후, 4℃에서 16시간 동안 반응시켰다. For ELISA analysis, the primary antibodies of IL(Interlukin)-6 and IL-8 were diluted in a volume ratio of 250:1 using a coating buffer, and then 100µl was dispensed into each well of a 96-well plate. Then, it was reacted at 4° C. for 16 hours.
그 후 0.1%(v/v)의 트윈 20(tween 20)이 함유된 1X PBST로 3회 세척한 후, 원심분리하여 획득하였던 상층액을 1차 항체가 코팅된 웰에 주입하고 2시간 동안 반응시켰다. 이후 다시 3회 세척과정을 거친 후, 각각의 1차 항체에 부합하는 2차 항체를 1시간 동안 반응시켰다. 반응 종료 후, H2O2 기질이 함유된 발색시약을 이용하여 발색 시킨 다음, 405nm 파장 아래 흡광도를 측정하였다.
Thereafter, after washing three times with 1X PBST containing 0.1% (v/v) of
4. 사과, 포도, 적색 파프리카 추출물 및 이들의 혼합물에 의한 항염증 효능 평가-아토피 피부염 동물모델 이용4. Evaluation of anti-inflammatory efficacy of apple, grape, red paprika extracts and mixtures thereof-using animal model of atopic dermatitis
6주령 수컷 BALB/c 마우스를 구입하여 일주일 동안 25±2℃, 습도 55±1% 조건하에 안정화시켰다. 그 후 마우스의 등을 제모한 다음, 제모된 마우스의 등에 100㎕의 DNFB(2,4-dinitrofluorobenzene)를 일주일에 2회, 5주 동안 점적하여 피부염을 유도하였다. 6-week-old male BALB/c mice were purchased and stabilized under conditions of 25±2° C. and 55±1% humidity for a week. Thereafter, the back of the mouse was depilated, and then 100 µl of DNFB (2,4-dinitrofluorobenzene) was instilled on the back of the depilated mouse twice a week for 5 weeks to induce dermatitis.
실험군은 Blank(피부염을 유도하지 않은 군), DNFB(DNFB로 피부염을 유도한 후 추출물을 투여하지 않은 군), 사과 100(DNFB를 도포하여 피부염을 유도하면서 사과 70%(v/v) 에탄올 추출물 100mg/kg을 경구투여한 군), 포도 100(DNFB를 도포하여 피부염을 유도하면서 포도 70%(v/v) 에탄올 추출물 100mg/kg을 경구투여한 군), 적색 파프리카 100(DNFB를 도포하여 피부염을 유도하면서 적색 파프리카 70%(v/v) 에탄올 추출물 100mg/kg을 경구투여한 군), 사과+포도+적색 파프리카 2:2:1(DNFB를 도포하여 피부염을 유도하면서 사과, 포도, 적색 파프리카 추출물을 2:2:1 중량비로 혼합한 혼합물 100mg/kg을 경구투여한 군) 및 사과+포도+적색 파프리카 1:1:1(DNFB를 도포하여 피부염을 유도하면서 사과, 포도, 적색 파프리카 추출물을 1:1:1 중량비로 혼합한 혼합물 100mg/kg을 경구투여한 군)로 나누어 실험하였으며, 100㎕의 DNFB 피부에 잠적하는 마지막 일주일 동안 매일 각각의 실험군별로 추출물 시료를 경구투여하여 피부염 정도를 확인하였고, 실험 마지막 날 마우스를 희생하여 등조직 및 혈액을 채집하였다.
The experimental group was blank (the group that did not induce dermatitis), DNFB (the group that did not administer the extract after inducing dermatitis with DNFB), apple 100 (the apple 70% (v/v) ethanol extract while inducing dermatitis by applying DNFB. 100mg/kg orally administered group), grape 100 (group orally administered grape 70% (v/v) ethanol extract 100mg/kg while inducing dermatitis by applying DNFB), red paprika 100 (dermatitis by applying DNFB) Red paprika 70% (v/v) ethanol extract 100mg/kg was administered orally while inducing the group), apple+grape+red paprika 2:2:1 (Apple, grape, red paprika while inducing dermatitis by applying DNFB) A mixture of 100 mg/kg of a mixture in which the extract was mixed in a 2:2:1 weight ratio was administered orally) and apple+grape+red paprika 1:1:1 (applying DNFB to induce dermatitis while inducing apple, grape, red paprika extracts) The experiment was conducted by dividing it into a group in which 100 mg/kg of a mixture mixed in a 1:1:1 weight ratio was administered orally), and the extract sample was orally administered to each experimental group every day during the last week of dormant in 100µl of DNFB skin to check the degree of dermatitis. On the last day of the experiment, mice were sacrificed to collect back tissue and blood.
실시예Example 1. 사과, 포도, 적색 파프리카 추출물의 독성 평가 1. Toxicity evaluation of extracts of apple, grape and red paprika
HaCaT 세포에 사과, 포도, 적색 파프리카 추출물을 농도별로 처리하여 세포독성을 확인하였다. 그 결과, 도 1에 개시된 바와 같이 사과 또는 포도 추출물은 0.1~1000㎍/mL 농도로 처리하여도 세포 독성이 나타나지 않았다. 적색 파프리카 추출물은 0.1~100㎍/mL 농도로 처리하였을 때는 세포 독성이 나타나지 않았으나, 1000㎍/mL 농도로 처리한 경우, 세포독성이 나타났다. 따라서 이후 실험에서는 사과, 포도, 적색 파프리카 추출물을 0.1~100㎍/mL의 농도로 실험에 사용하였다.
HaCaT cells were treated with apple, grape, and red paprika extracts at different concentrations to confirm cytotoxicity. As a result, as disclosed in FIG. 1, even when the apple or grape extract was treated at a concentration of 0.1 to 1000 μg/mL, cytotoxicity was not observed. Red paprika extract did not show cytotoxicity when treated at a concentration of 0.1-100µg/mL, but when treated at a concentration of 1000µg/mL, cytotoxicity was observed. Therefore, in subsequent experiments, apple, grape, and red paprika extracts were used in the experiment at a concentration of 0.1-100㎍/mL.
실시예Example 2. 2. HaCatHaCat 세포에서 사과, 포도, 적색 파프리카 추출물의 항염증 효능 평가 Evaluation of anti-inflammatory efficacy of apple, grape and red paprika extracts in cells
사과, 포도 및 적색 파프리카 추출물의 항염증 활성 탐색을 위해 ELISA 실험 방법을 활용하여 HaCaT 세포에서 분비되는 염증성 사이토카인의 양을 측정하였다. To investigate the anti-inflammatory activity of apple, grape and red paprika extracts, the amount of inflammatory cytokines secreted from HaCaT cells was measured using an ELISA test method.
HaCaT 세포에 각각의 추출물을 다양한 농도(0.1, 1 및 10㎍/mL)로 전처리한 후 TNF(tumor necrosis factor)-α와 IFN(interferon)-γ를 18시간 동안 처리하여 유도된 염증성 사이토카인(IL-6 및 IL-8)의 분비량 변화를 확인하였다. HaCaT cells were pretreated with various concentrations (0.1, 1 and 10㎍/mL) of each extract and then treated with TNF (tumor necrosis factor)-α and IFN (interferon)-γ for 18 hours to induce inflammatory cytokines ( IL-6 and IL-8) was confirmed.
그 결과, 도 2에 개시된 바와 같이 사과, 포도 및 적색 파프리카 추출물은 모든 농도에서 염증성 사이토카인의 분비량을 감소시켰다.
As a result, as disclosed in FIG. 2, apple, grape, and red paprika extracts reduced the secretion of inflammatory cytokines at all concentrations.
실시예Example 3. 아토피 피부염 동물모델에서 사과, 포도, 적색 파프리카 추출물 및 이들의 혼합물에 의한 항염증 효능 평가 3. Evaluation of anti-inflammatory efficacy of apple, grape, red paprika extracts and mixtures thereof in an animal model of atopic dermatitis
사과, 포도, 적색 파프리카 추출물 및 이들의 혼합물에 의한 아토피 피부염 개선효과를 확인하기 위해 DNFB를 이용하여 제모된 마우스의 등 피부에 아토피 피부염을 유발한 후, 각 추출물을 경구투여하였다.In order to confirm the effect of improving atopic dermatitis by apple, grape, red paprika extracts, and mixtures thereof, after inducing atopic dermatitis on the back skin of a mouse depilated using DNFB, each extract was orally administered.
그 결과, 도 3에 개시된 바와 같이 0.15% DNFB로 아토피성 피부염을 유도한 DNFB 군에서 아토피성 피부염 유도로 인한 피부 각질화, 염증 반응에 따른 출혈증상이 관찰되었다. As a result, as shown in FIG. 3, in the DNFB group inducing atopic dermatitis with 0.15% DNFB, skin keratinization due to induction of atopic dermatitis and bleeding symptoms according to inflammatory reaction were observed.
0.15% DNFB로 아토피성 피부염을 유도한 후 사과, 포도 및 적색 파프리카 단독 추출물을 투여한 군 및 이들의 혼합물을 경구투여를 한 군에서는 아토피성 피부염 유도에 따른 피부 각질화 및 출혈 증상이 호전되는 것을 확인할 수 있었으며, 특히 사과, 포도 및 적색 파프리카 추출물을 1:1:1의 중량비로 혼합하여 경구투여한 군에서 아토피 피부염 개선효과가 현저하였다. After inducing atopic dermatitis with 0.15% DNFB, it was confirmed that skin keratinization and bleeding symptoms improved due to induction of atopic dermatitis in the group administered with apple, grape, and red paprika alone extract and the group administered orally with a mixture thereof. In particular, the atopic dermatitis improvement effect was remarkable in the group administered orally by mixing apple, grape and red paprika extracts at a weight ratio of 1:1:1.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190025600A KR102510158B1 (en) | 2019-03-06 | 2019-03-06 | Anti-atopic dermatitis composition comprising mixture of plant extract as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190025600A KR102510158B1 (en) | 2019-03-06 | 2019-03-06 | Anti-atopic dermatitis composition comprising mixture of plant extract as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200108125A true KR20200108125A (en) | 2020-09-17 |
| KR102510158B1 KR102510158B1 (en) | 2023-03-16 |
Family
ID=72707118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190025600A KR102510158B1 (en) | 2019-03-06 | 2019-03-06 | Anti-atopic dermatitis composition comprising mixture of plant extract as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102510158B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003231640A (en) * | 2002-02-04 | 2003-08-19 | Unitika Ltd | Agent for treatment of atopic dermatitis |
| KR101682394B1 (en) * | 2016-04-18 | 2016-12-05 | 씨앤텍 주식회사 | Cosmetic composition comprising color food extracts |
-
2019
- 2019-03-06 KR KR1020190025600A patent/KR102510158B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003231640A (en) * | 2002-02-04 | 2003-08-19 | Unitika Ltd | Agent for treatment of atopic dermatitis |
| KR101682394B1 (en) * | 2016-04-18 | 2016-12-05 | 씨앤텍 주식회사 | Cosmetic composition comprising color food extracts |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102510158B1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6533575B2 (en) | Inflammasome activation inhibitor | |
| KR101364234B1 (en) | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising the extract Daphne genkwa, fraction of thereof or compound isolated therefrom as an active ingredient | |
| KR20110136387A (en) | Compositions for prevention and treatment of allergic disease comprising the fractions from the extracts of gardenia jasminoides as an active ingredient | |
| KR101330411B1 (en) | Composition for improving atopic dermatitis comprising extract of steamed green tea | |
| KR101419464B1 (en) | The composition comprising the extract or fraction of Pleurotus eryngii var. ferulae for prevention of anti aging as an active ingredient | |
| KR20120118188A (en) | Compostion for reducing irritation and inflammaion in skin comprising extracts of astragalus membranaceus | |
| KR20180041887A (en) | Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Diospyros lotus leaf and grape fruit stem as effective component | |
| KR101115502B1 (en) | The composition for prevention and treatment of hypersensitive skin disease containing Plantago asiatica Extract as an active ingredient | |
| KR20120077889A (en) | Composition for prevention or treatment of atopic dermatitis comprising an extract of pine leaf or pine gnarl | |
| KR100670850B1 (en) | Composition containing Gentianae Macrophyllae Radix Extract for treatment hypersensitive skin disease | |
| KR20170091804A (en) | Composition for treating, improving or preventing allergic disease | |
| KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
| KR20060102621A (en) | Composition containing sanguisorba officinalis extract for treatment hypersensitive skin disease | |
| KR101213054B1 (en) | Composition for the prevention and treatment of apotic dermatitis containing the mixed extract of Chrysanthemum indicum Linne. and steamed Rheum undulatum with alcohol as an effective ingredient | |
| KR102156543B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising Rosa davurica extract as effective component | |
| KR102510158B1 (en) | Anti-atopic dermatitis composition comprising mixture of plant extract as effective component | |
| KR20150113632A (en) | Composition for improving skin conditions and method for improving skin conditions using the same | |
| KR101844890B1 (en) | Composition for preventing or improving atopic dermatitis comprising ethyl acetate fraction of methanol extract from Diospyros lotus leaf as effective component | |
| KR102144566B1 (en) | A composition for preventing or terating atopic dermatitis comprising lycopi herba extract as an active ingredient | |
| KR102106440B1 (en) | Composition for improving skin condition comprising blueberry and black rice extract fermented lactic acid bacteria | |
| KR20210058760A (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
| KR101115503B1 (en) | The composition for prevention and treatment of hypersensitive skin disease containing Fraxini Cortex Extract as an active ingredient | |
| KR20220014372A (en) | Composition for inhibiting sebum secretion comprising ellagic acid extract as an active ingredient | |
| KR20200089527A (en) | Composition comprising extracts of Acorus gramineus and Dendropanax morbifera for anti-inflammation | |
| KR102213459B1 (en) | Anti-atopic composition comprising extract of pepper seed meal as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |